GMAB Stock Analysis: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$28.52
0.88 (3.17%)
▲
5d:
+9.09%
30d:
+19.56%
90d:
+4.76%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GMAB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: GMAB shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.53
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$36.96
22.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $28.52, which is considered extended relative to its 30-day fair value range of $24.59 to $26.81. The stock's valuation (Forward PE: 15.6) is in line with its historical norms (16.7). Remarkably, the market is currently pricing in an annual earnings decline of 2.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMAB is in a downtrend. The price is approaching resistance at $28.78. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $36.82 (+29.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GMAB is in a downtrend. The price is approaching resistance at $28.78. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $36.82 (+29.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$24.59 -
$26.81
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
51.0%
All Signals
- BEARISH: Price extended above range (+6.4% above its trading range)
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.2%)
- BULLISH: Trading 29.1% below Wall St target ($36.82)
Trading Range Analysis
30-Day Trading Range
$24.59 -
$26.81
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$24.88
Resistance Level
$28.78
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.58
Wall Street Target
$36.82
(+29.1%)
Revenue Growth (YoY)
25.3%
Earnings Growth (YoY)
-72.8%
Profit Margin
21.1%
Valuation Discount vs History
-2.3% cheaper
PE vs Historical
15.6 vs 16.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.3%
(market-implied from PE analysis)
1-Year Target
$27.86
(-2%)
2-Year Target
$27.22
(-5%)
3-Year Target
$26.59
(-7%)
3-Yr Target (if PE normalizes)
(PE: 16→17)
$28.51
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 75.8%)
$134.56
(+372%)
Base:
(SPY PE: 15.6, Growth: 75.8%)
$96.24
(+238%)
Bear:
(PE: 13.2, Growth: 75.8%)
$81.80
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 20.94 | Current EPS (TTM): $1.32
Bull Case
$42.16
(+48%)
Analyst growth 38.7%, PE expands to 23.0
Base Case
$38.33
(+34%)
Market implied 38.7%, PE stable at 20.9
Bear Case
$18.80
(-34%)
Severe decline -20.0%, PE contracts to 17.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.6 to 16.7
Stabilization Target:
$30.57
(+7.2%)
PE Expansion Potential:
+7.2%
Share & Embed Analysis
Last updated: July 03, 2026 10:14 PM ET
Data refreshes hourly during market hours. Next update: 11:14 PM
Data refreshes hourly during market hours. Next update: 11:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 51 HOLD |
